Search Results

March 21, 2016

Real-World Data on XARELTO® in Patients with Non-Valvular Atrial Fibrillation and Diabetes Among 14 Presentations at American College of Cardiology’s 65th Annual Scientific Session

New data add to growing body of real-world evidence supporting physicians and hospitals in optimizing patient care for those at risk of stroke or blood clots

Innovative Medicine

March 7, 2016

Real-World Study Found XARELTO® Led to Cost Savings and Shorter Stays in U.S. Hospitals Compared to Warfarin When Used for Treatment of Blood Clots

Findings from this cost savings analysis add to research confirming value of XARELTO® (rivaroxaban) in reducing cost burden to healthcare systems

Innovative Medicine

February 24, 2016

First Regimen Combining Long Acting Injectable Antiretrovirals; 32-Week LATTE 2 Study Results Presented at CROI

Intramuscular 2-drug maintenance therapy demonstrates comparable antiviral activity to daily oral 3-drug combination

Innovative Medicine

December 18, 2015

Janssen Announces Collaboration with Bavarian Nordic to Develop Vaccine for Chronic Human Papillomavirus (HPV) Infections

New approach for early treatment and interception of HPV-induced cancers

Innovative Medicine

December 7, 2015

First Data Unveiled from CALLISTO Program Examining the Use of XARELTO® (rivaroxaban) for Treating Blood Clots in People with Cancer

First of Nine Studies, Examining the Ability of Rivaroxaban to Reduce the Burden of Cancer-Associated Blood Clots, Presented at ASH Annual Meeting

Innovative Medicine

December 7, 2015

Real-World Data Confirms Safety and Efficacy Profile of XARELTO®, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis

XALIA is First Prospective Study to Confirm Benefit of a Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) for Treating Deep Vein Thrombosis in Routine Clinical Practice, Adds to More than 91,000 Patients Enrolled in Real-World Studies

Innovative Medicine

November 30, 2015

Janssen Submits Applications Seeking Approval Of STELARA®In United States And European Union For Crohn’s Disease

Innovative Medicine

November 16, 2015

DARZALEX® (daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma

First-in-class immunotherapy approved for multiple myeloma patients who have received three or more prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and immunomodulatory agent

Innovative Medicine

November 13, 2015

Largest Schizophrenia and Schizoaffective Disorder Caregiver Survey Reveals Overwhelming Burden and Inadequate Assistance

Findings Highlight Need for Education and More Support for Caregivers

Innovative Medicine

November 9, 2015

Janssen Announces Global License and Development Rights Agreement with Hanmi Pharmaceutical for Novel Clinical Stage Biologic to Treat Diabetes and Obesity

Novel Oxyntomodulin-Based Therapy Bolsters Janssen’s Metabolism Portfolio

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine